Bragar Eagel &amp; Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Boston Scientific (BSX) To Contact Him Directly To Discuss Their Options  If you are a long-term stockholder

BOSTON SCIENTIFIC ALERT: Bragar Eagel & Squire, P.C. is Investigating Boston Scientific Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Boston Scientific Facing Class Action Over Misleading Growth Statements

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Bragar Eagel &amp;amp; Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Boston Scientific (BSX) To Contact Him Directly To Discuss Their Options  If you are a long-term stockholder</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Boston Scientific is under investigation for potential misleading statements about its U.S. electrophysiology segment&#039;s growth, which may have breached fiduciary duties. The implications could affect the company’s stock price and investor confidence, especially as competition intensifies in the sector.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Boston Scientific faces a class action lawsuit regarding misleading statements.</li><li>Allegations include unsustainable growth claims in its U.S. EP segment.</li><li>New competition is impacting Boston Scientific&#039;s market share significantly.</li><li>Investors may have claims against the board for breaching fiduciary duties.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Boston Scientific (BSX)</strong>: Facing potential legal issues impacting market perception and stock valuation.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>This news falls under legal issues, highlighting the company&#039;s current vulnerabilities and risks that could impact its stock price significantly.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Class action outcomes could lead to significant legal costs for Boston Scientific.</li><li>Weak performance in the U.S. EP segment may further diminish investor confidence.</li><li>Growth outlook changes can drastically impact BSX’s stock valuation.</li><li>Increased competition in the EP market could reduce Boston Scientific&#039;s revenue projections.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Class Period is from July 23, 2025, to February 3, 2026.</li><li>Allegations claim multiple misleading statements were made during this period.</li><li>Class action filed on March 5, 2026.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider a cautious stance on BSX, with potential downward pressure in the short term.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify"><strong>Bragar Eagel &amp; Squire, P.C. </strong><strong>Litigation Partner </strong><a href="https://www.globenewswire.com/Tracker?data=nsenDwAsILHaaKzcxZKP0-tptkyAXdwxioHrfadaKGOUoNQl_zyGyyhP7CQH3Q5RQtz_DuEDOOYxeKjA-YYU1qtRGYuO8I0r8UMQjcf1ZG9kkbShKlnIX-F-loIZvrob" rel="nofollow" target="_blank"><strong>Brandon Walker</strong></a><strong> Encourages Investors Who Suffered Losses In Boston Scientific (BSX) To Contact Him Directly To Discuss Their Options</strong></p>  <p align="justify"><strong>If you are a long-term stockholder in </strong><strong>Boston Scientific</strong><strong> and would like to discuss your legal rights, call Bragar Eagel &amp; Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.</strong></p>  <p align="justify">Click <a href="https://www.globenewswire.com/Tracker?data=nXadLEYGaY3AtOhjebWqcGGrFvhDCmKVX7G1NkjRpZTNe5o1Fig0ygWlKZGwsbFJoc2qhdk-uK5bvYw2-3UOEw==" rel="nofollow" target="_blank">here</a> to participate in the action.</p>  <p align="justify">NEW YORK, April  08, 2026  (GLOBE NEWSWIRE) -- </p>  <p align="justify"><strong>What's Happening:</strong></p>  <ul type="circle"><li style="margin-bottom:12pt; text-align:justify;"><a href="https://www.bespc.com" rel="nofollow" target="_blank">Bragar Eagel &amp; Squire, P.C</a>., a nationally recognized shareholder rights law firm, is investigating potential claims against Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/BSX">BSX</a>) on behalf of long-term stockholders following a class action complaint that was filed against Boston Scientific on March 5, 2026 with a Class Period from July 23, 2025, to February 3, 2026. Our investigation concerns whether the board of directors of Boston Scientific have breached their fiduciary duties to the company.<br></br></li></ul>  <p align="justify"><strong>Details:</strong></p>  <ul type="circle"><li style="margin-top:5pt; margin-bottom:12pt; text-align:justify;">The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Boston Scientific's U.S. EP segment's growth rate was unsustainable and was approaching an earlier tipping point than the market was anticipating; (2) the Company was experiencing new competition entrants that were sapping Boston Scientific's U.S. Electrophysiology market share and thus limiting the Company's growth potential; (3) as a result, Defendants' repeated statements of confidence in the U.S. EP division's growth trajectory, including repeatedly elevated full-year guidance metrics, were materially misleading; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.<br></br></li></ul>  <p align="justify"><strong>Next Steps:</strong></p>  <ul type="circle"><li style="text-align:justify;">If you are a long-term stockholder of Boston Scientific, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact <a href="https://www.bespc.com/professionals/brandon-walker" rel="nofollow" target="_blank">Brandon Walker</a> or <a href="https://www.bespc.com/professionals/melissa-fortunato" rel="nofollow" target="_blank">Melissa Fortunato</a> by email at <a href="mailto:investigations@bespc.com" rel="nofollow" target="_blank">investigations@bespc.com</a>, by telephone at (212) 355-4648, or by <a href="https://www.bespc.com/cases/BSX" rel="nofollow" target="_blank">filling out this contact form</a>. There is no cost or obligation to you.<br></br></li></ul>  <p align="justify"><strong>About Bragar Eagel &amp; Squire, P.C.:</strong></p>  <p align="justify">Bragar Eagel &amp; Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit <a href="https://www.globenewswire.com/Tracker?data=wkBD_4Zlp1A2f9MJ8j5EatzOuRIKFbAUryjI5KdtnQSYrInlcAGkhN4LMjv3snzQwDYZqnTG2UIrlLz2lkLVRg==" rel="nofollow" target="_blank">www.bespc.com</a>.  Attorney advertising.  Prior results do not guarantee similar outcomes.</p>  <p align="justify">Follow us for updates on <a href="https://www.globenewswire.com/Tracker?data=8LpdA1e74bdDKlVPcFq-JQ6oVMG3KklZhXEd83tCJ0KKgO0D7pqRb4AGoJ6BYKAUzP8StCFOxIZwjyp6Ui9ZIzuNJVBTUCgrQBak0h11s2E4ebg8SzKCTrhDHfkIOvel" rel="nofollow" target="_blank">LinkedIn</a> and <a href="https://www.globenewswire.com/Tracker?data=6axcpEFjA2IsBtubTAKrKSKs_4IRTTrYVL1Wk-2532-TniGf-wygdDJNLmsXfAWZxWARnLik7T3Ju1prKy02oSHTkZI_P0LN1I6fqHsOcZrxQai5CKh74mOnUtXm4jCj" rel="nofollow" target="_blank">Facebook</a>, and keep up with other news by following Brandon Walker, Esq. on <a href="https://www.globenewswire.com/Tracker?data=8LpdA1e74bdDKlVPcFq-JQ7MvKhOSo1f6LN7dKiI8PhF94kiFnbTBOrwwqWsMBHpn35gILD_pAzqiAz1yjKg1NP725edL987zM07EUjuEONGTZ2cnpCTS6aOvN4S1Qnp" rel="nofollow" target="_blank">LinkedIn</a>.</p>  <p align="justify"><strong>Contact Information:</strong></p>  <p align="justify">Bragar Eagel &amp; Squire, P.C.<br></br>Brandon Walker, Esq.<br></br>Melissa Fortunato, Esq.<br></br>(212) 355-4648<br></br><a href="https://www.globenewswire.com/Tracker?data=fdwtpMVjDJytksOEbpBxzB3YweAAwCNu0CMNlQ5jtyTUU8MvpBEGVrfN6gY4B9GTGrTay2FucSEZ03I9nfGZcTAc6VnxrCmFDlAQVpHbbtfyweOGbWocxaEoUIQ5SwvE" rel="nofollow" target="_blank"><u>investigations@bespc.com</u></a><br></br><a href="https://www.globenewswire.com/Tracker?data=wkBD_4Zlp1A2f9MJ8j5EaotSNDw3PnJjCXZcb2TLkR_ermRi6C2NhNom1PwTglJOsivI5odQT4F5v5Pqq9dg0Q==" rel="nofollow" target="_blank"><u>www.bespc.com</u></a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY4NjQ3MiM3NTI2MjgwIzIxMDAzOTg="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/YzhlZmFkMzgtYWUyYy00ZjM1LWFlZTktYjQyNWRhNWMxZWQ4LTExMTE5NjktMjAyNi0wNC0wOC1lbg==/tiny/Bragar-Eagel-Squire.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/29481954-f2ff-4756-b5a9-d982a6497bd0"><img src="https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg" border="0" width="150" height="75" alt="Primary Logo"></img></a></p>

Boston Scientific is under investigation for potential misleading statements about its U.S. electrophysiology segment's growth, which may have breached fiduciary duties. The implications could affect the company’s stock price and investor confidence, especially as competition intensifies in the sector.

boston-scientific-alert-bragar-eagel-squire-p-c-is-investigating-boston-scientific-corporation-on-behalf-of-long-term-stockholders-and-encourages-investors-to-contact-the-firm

BOSTON SCIENTIFIC ALERT: Bragar Eagel & Squire, P.C. is Investigating Boston Scientific Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Legal

Related News